Liquid Biopsy: Basic Research and Clinical Utility
A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Precision Oncology".
Deadline for manuscript submissions: 30 November 2026 | Viewed by 460
Special Issue Editor
Interests: cancer research; non-coding RNAs; 3-D cell culture models; transcription factor
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
We are pleased to invite you to contribute to this Special Issue focused on liquid biopsies and their relation to basic research and clinical utility.
Over recent years, liquid biopsies have been an emerging field of research, and their utility has been proven in medical practice. A liquid biopsy can be collected from any biological fluid, like blood, urine, saliva, and cerebrospinal fluid. In general, liquid biopsies offer several advantages over traditional tissue biopsies, e.g., liquid biopsies are less invasive and can be performed repeatedly for real-time monitoring of disease progression and treatment responses. Furthermore, liquid biopsies have the power to provide a more comprehensive view of tumour heterogeneity and support the early detection, treatment selection, and identification of resistance mechanisms.
The importance of liquid biopsies, especially in the field of personalised medicine, is underlined by several FDA-approved tests used to identify genetic changes in tumours by analysing circulating tumour DNA (ctDNA) from blood samples. These tests can act as companion diagnostics to determine if a patient is eligible for specific targeted therapies or can be used for general tumour profiling to inform treatment decisions and clinical trial eligibility. Other approved tests include a personalised, tumour-informed test used for minimal residual disease monitoring; a mutation test for non-small cell lung cancer; a circulating tumour cell (CTC) test for certain metastatic cancers; and CancerSEEK, targeting cell-free DNA (cfDNA) and protein biomarkers for early multi-cancer detection. As illustrated by these examples, liquid biopsies can be used to analyse a broad variety of molecules, including ctDNA, cfDNA, CTCs, and proteins.
This Special Issue will present a collection of new liquid biopsy-based research and applications in the medical field, as well as reviews about this fast-moving field in the interplay between the bench and bedside. The aim of this Special Issue is to provide an up-to-date overview of liquid biopsies, summarising their power as a tool in personalised medicine and providing a look into the future of this fascinating technology.
Dr. Jens Claus Hahne
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- liquid biopsy
- circulating tumour cells (CTCs)
- circulating tummour DNA (ctDNA)
- cell free DNA (cfDNA)
- non-coding RNAs
- protein biomarker
- personalised medicine
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
